anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Activation of myofibroblasts, linked to oxidative stress, emerges as a pivotal role in the progression of pulmonary fibrosis (PF). Our prior research has underscored the therapeutic promise of tanshinone IIA (Tan-IIA) in mitigating PF by enhancing nuclear factor-erythroid 2-related factor 2 (Nrf2) activity. Nevertheless, the molecular basis through which Tan-IIA influences Nrf2 activity has yet to be fully elucidated.
METHODS: The influence of Tan-IIA on PF was assessed in vivo and in vitro models. Inhibitors, overexpression plasmids, and small interfering RNA (siRNA) were utilized to probe its underlying mechanism of action in vitro.
RESULTS: We demonstrate that Tan-IIA effectively activates the kelch-like ECH-associated protein 1 (Keap1)-Nrf2 antioxidant pathway, which in turn inhibits myofibroblast activation and ameliorates PF. Notably, the stability and nucleo-cytoplasmic shuttling of Nrf2 is shown to be dependent on augmented autophagic flux, which is in alignment with the observation that Tan-IIA induces autophagy. Inhibition of autophagy, conversely, fosters the activation of extracellular matrix (ECM)-producing myofibroblasts. Further, Tan-IIA initiates an autophagy program through the sestrin 2 (Sesn2)-sequestosome 1 (Sqstm1) signaling axis, crucial for protecting Nrf2 from Keap1-mediated degradation. Meanwhile, these findings were corroborated in a murine model of PF.
CONCLUSION: Collectively, we observed for the first time that the Sqstm1-Sesn2 axis-mediated autophagic degradation of Keap1 effectively prevents myofibroblast activation and reduces the synthesis of ECM. This autophagy-dependent degradation of Keap1 can be initiated by the Tan-IIA treatment, which solidifies its potential as an Nrf2-modulating agent for PF treatment.
Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
The proposed study aims to advance the understanding of Post-COVID treatment using a randomized cross-over design to evaluate the taVNS-induced changes over 12 weeks. A hundred twenty patients diagnosed with Long/Post-COVID are randomly assigned to one of three groups related to the two arms of the study ("Monitoring with low/high-intensity stimulation" vs. Monitoring without stimulation"). In the treatment group, forty patients will start with high-intensity taVNS for 6 weeks, then switch to low-intensity stimulation for an additional 6 weeks. Another 40 patients begin with low-intensity stimulation for 6 weeks, followed by high-intensity taVNS stimulation. The control group ("Monitoring without stimulation") is able to receive taVNS after participation in the study.

The treatment group and the control group will participate in the same monitoring procedures. All participants will attend an initial laboratory session to complete several baseline assessments, including questionnaires, measuring energy expenditure via indirect calorimetry and completing a body silhouette task. Blood samples are taken at every session to evaluate changes in metabolic and inflammatory markers. To assess the motivation to work for rewards, the investigators employ an effort-based-cost-benefit paradigm (Effort Allocation Task). All these lab assessments will be repeated after 6 and 12 weeks to evaluate stimulation-induces changes in primary and secondary outcomes. In addition, all participants are given a cardio bracelet to monitor physiological parameters (e.g. heart rate, heart rate variability, breathing, skin conductance, step counts) over the study period. Over the 12 weeks, the treatment group will self-administer taVNS for four hours daily in a targeted manner, anticipating forthcoming exertion and stimulating in anticipation of an effortful event to enhance the patients' motivational drive and recovery. Another essential part of the study is the monitoring over the 12 weeks. All participants will complete daily ecological momentary assessments via smartphone to monitor their mental states. In addition, participants will perform once a day one of two discounting games (effort or temporal discounting task) to investigate changes in their decision behavior over time. The effort discounting task is essential to assess the motivation of post-COVID patients to pursue subjectively effortful situations over the 12 weeks.
BACKGROUND/AIMS: The incidence of acute gastrointestinal bleeding (GIB) increases with the utilization of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs). This study aimed to compare the risk of GIB between anticoagulant and NSAIDs combotherapy and anticoagulant monotherapy in real-world practice.
METHODS: We investigated the relative risk of GIB in individuals newly prescribed anticoagulant and NSAIDs combination therapy and that in individuals newly prescribed anticoagulant monotherapy at three hospitals using "common data model." Cox proportional hazard models and Kaplan-Meier estimation were employed for risk comparison after propensity score matching.
RESULTS: A comprehensive analysis of 2,951 matched pairs showed that patients who received anticoagulant and NSAIDs combousers exhibited a significantly higher risk of GIB than those who received anticoagulant monousers (hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.30 to 2.12; p<0.001). The risk of GIB associated with anticoagulant and NSAIDs combination therapy was also significantly higher than that associated with anticoagulant monotherapy in patients aged >65 years (HR, 1.53; 95% CI, 1.15 to 2.03; p=0.003) and >75 years (HR, 1.89; 95% CI, 1.23 to 2.90; p=0.003). We also found that the risk of GIB was significantly higher in the patients who received anticoagulant and NSAIDs combousers than that in patients who received anticoagulant monousers in both male (p=0.016) and female cohorts (p=0.010).
CONCLUSIONS: The risk of GIB is significantly higher in patients who receive anticoagulant and NSAIDs combotherapy than that in patients who receive anticoagulant monotherapy. In addition, the risk of GIB associated with anticoagulant and NSAIDs combotherapy was much higher in individuals aged >75 years. Therefore, physicians should be more aware of pay more attention to the risk of GIB when they prescribe anticoagulant and NSAIDs.
PURPOSE: To evaluate the tilt and decentration of intraocular lenses (IOLs) in eyes that underwent phacovitrectomy for macula-off rhegmatogenous retinal detachment (RRD) repair.
METHODS: In this retrospective cohort study, 63 patients with macula-off RRD who underwent phacovitrectomy were enrolled and divided into a primary implantation group (group A) and a delayed implantation group (group B) according to the time of IOL implantation. Routine ocular examinations, including optometry, were performed, and the IOL tilt and decentration were measured. Postoperative refractive prediction error and IOL tilt and decentration were compared between the two groups, and the relevant factors of IOL positions were analyzed.
RESULTS: The mean spherical refractive prediction error (MSE) was - 0.53 ± 0.39 D in group A and - 0.09 ± 0.55 in group B. The mean absolute spherical refractive prediction error (MASE) was 0.61 ± 0.23 D in group A and 0.50 ± 0.22 D in group B. The difference in MSE ( t = -3.623, P < 0.05) but not in MASE (t = 1.866, P = 0.067) between the two groups was significant. The mean IOL tilt and mean decentration were 8.54° ±3.65° and 0.55 ± 0.18 mm in group A and 10.62° ±3.29° and 0.66 ± 0.14 mm, respectively, in Group B. Differences in tilt ( t = -2.373, P < 0.05) and decentration ( t = -2.698, P < 0.05) between the two groups were both significant. In group B, the mean time interval between phacovitrectomy and IOL implantation (T V-I ) was 25.2 ± 6.9 weeks, and the absolute values of both IOL tilt and decentration were positively correlated with T V-I .
CONCLUSION: In phacovitrectomy for macula-off RRD repair, primary IOL implantation leads to a postoperative myopic shift, while delayed IOL implantation may cause greater IOL tilt and decentration.
Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g. , for reduced antibody-dependent cellular cytotoxicity (ADCC) induction, increased stability, and/or the ability to form heterodimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. Also provided are various embodiments relating to contiguous polypeptides comprising one or more variant GLP 1 polypeptide(s) having improved serum half-life. Further provided are various embodiments relating to contiguous polypeptides or heterodimeric polypeptides comprising a GLP 1 polypeptide and a glucagon polypeptide as a dual GLP 1 receptor and glucagon receptor agonist. In various embodiments, such polypeptides may be used to treat, for example, diabetes, obesity, or related indications, in companion animals, such as canines, felines, and equines.
The invention discloses a Chinese herbal medicinal preparation for relieving ulcer by inhibiting gastric acid, which is prepared from the following raw materials in part by weight: 200 parts of birch bark and 50 to 100 parts of caramel. The birch bark is bark of white birch which belongs to betulo. In addition, the invention also provides the preparation method of the Chinese herbal medicinal preparation. The Chinese herbal medicinal preparation is prepared by pure Chinese medicines and therefore is from toxic and side effects. The formula of the Chinese herbal medicinal preparation is simple, the treatment effect of the Chinese herbal medicinal preparation is reliable, the preparation process of the Chinese herbal medicinal preparation is simple and the production cost of the Chinese herbal medicinal preparation is low. The Chinese herbal medicinal preparation has the characteristics of quick gastric acid inhibition, short treatment period and low price. The Chinese herbal medicinal preparation has the functions of restraining gastric acid, healing ulcer, soothing stomach, relieving pain, stopping blood and tonifying blood, and is mainly used for treating gastric ulcer, bleeding stomach ulcer, hyperchlorhydria and chronic gastritis. The Chinese herbal medicinal preparation can enter stomach and directly act on lesions and therefore can treat ulcer quickly.
PROBLEM TO BE SOLVED: To efficiently obtain a stable dissolved material of a lipophilic material for a short time by treating a cyclodextrin(CD) and the lipophilic material by a wet jet mill. SOLUTION: Though the lipophilic material is not restricted, particularly, vitamin E, soybean oil, docosa-hexaenoic acid and the like are cited. As the cyclodextrin(CD), at least one kind selected from the group of α-, β- and γ-CD composed of respectively 6 molecules, 7 molecules and 8 molecules of glucose, their sugar modified materials and chemically modified materials is cited. In the addition of the CDs, the one combined with at least one kind selected from the group composed of the sugar modified materials and the chemically modified materials obtained by replacing at least >=1 of these hydroxyl group with at least >=1 of functional groups can be used. When producing a clathrate compound of CD with the lipophilic material, the wet jet mill is used for the process. As a result, the excellently stable dissolved material is efficiently produced for a short time.
PURPOSE:To provide a cosmetic having excellent emulsion stability, applicability and safety to the skin, by neutralizing and thickening a water-soluble carboxyvinyl polymer with an amino sugar. CONSTITUTION:A cosmetic useful as a skin or hair cosmetic of transparent gel- type or opaque emulsion-type, is prepared by compounding (A) a water-soluble carboxyvinyl polymer and (B) an amino sugar such as D-glucosamine, D-galactosamine, D-mannosamine, etc. The amount of (A) is preferably about 0.005- 10.0wt% especially 0.01-2.0wt% based on the whole cosmetic, and that of (B) is 0.1-10 times weight, especially 0.3-3.0 times weight, based on the component (A). The component (A) is neutralized and thickened with the component (B) in the cosmetic, and the cosmetic is transparent when the oil content is extremely low, and is opaque otherwise. In each case, the cosmetic has a glossy and desirable appearance. It is safe to the skin, has moistening effect, gives moist feeling to the skin, and exhibits excellent stability by the thickening of the component (A).
The acute toxicity of isoproterenol hydrochloride in animals is much less than that of epinephrine. Excessive doses in animals or man can cause a striking drop in blood pressure, and repeated large doses in animals may result in cardiac enlargement and focal myocarditis.

In case of accidental overdosage as evidenced mainly by tachycardia or other arrhythmias, palpitations, angina, hypotension, or hypertension, reduce rate of administration or discontinue isoproterenol hydrochloride injection until patient’s condition stabilizes. Blood pressure, pulse, respiration, and ECG should be monitored.

It is not known whether isoproterenol hydrochloride is dialyzable.

The oral LD50 of isoproterenol hydrochloride in mice is 3,850 mg/kg ± 1,190 mg/kg of pure drug in solution.
Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
Segmenting polyps from colonoscopy images is very important in clinical practice since it provides valuable information for colorectal cancer. However, polyp segmentation remains a challenging task as polyps have camouflage properties and vary greatly in size. Although many polyp segmentation methods have been recently proposed and produced remarkable results, most of them cannot yield stable results due to the lack of features with distinguishing properties and those with high-level semantic details. Therefore, we proposed a novel polyp segmentation framework called contrastive Transformer network (CTNet), with three key components of contrastive Transformer backbone, self-multiscale interaction module (SMIM), and collection information module (CIM), which has excellent learning and generalization abilities. The long-range dependence and highly structured feature map space obtained by CTNet through contrastive Transformer can effectively localize polyps with camouflage properties. CTNet benefits from the multiscale information and high-resolution feature maps with high-level semantic obtained by SMIM and CIM, respectively, and thus can obtain accurate segmentation results for polyps of different sizes. Without bells and whistles, CTNet yields significant gains of 2.3%, 3.7%, 3.7%, 18.2%, and 10.1% over classical method PraNet on Kvasir-SEG, CVC-ClinicDB, Endoscene, ETIS-LaribPolypDB, and CVC-ColonDB respectively. In addition, CTNet has advantages in camouflaged object detection and defect detection. The code is available at https://github.com/Fhujinwu/CTNet.
The invention discloses a simvastatin and ezetimibe compound nano solution and freeze-dried powder and a preparation method of the solution and belongs to the field of medicine preparations. The nano solution is characterized by being prepared from 5-20 parts of simvastatin, 5-15 parts of ezetimibe, 80-240 parts of a carrier material, 150-750 parts of surfactant and 15-35 parts of an organic solvent, the average particle size of the nano solution is 126 nm or below, and the polydispersity index (PDI) is 0.4 or below. The selected carrier material and the surfactant are good in biocompatibility and small in toxicity and are ideal auxiliary materials. The selected organic solvent can well volatilize and be well removed and is small in toxicity. The compound nano solution is prepared from simvastatin and ezetimibe, a freeze-drying protective agent is added, and the freeze-dried powder is prepared through the freeze-drying method, so that stability of the nano solution is improved, and water solubility and bioavailability are improved. 2800-4800 parts of the freeze-drying protective agent is added, the average particle size of the nano solution is 650 nm or below after the freeze-dried powder is redissolved, and the polydispersity index is 0.7 or below. In the preparation process, the organic solvent is effectively removed through the heating volatilization method, remaining of the organic solvent is avoided, and meanwhile the system is more stable.
Control group (n = 16 nursing homes, 64 patients): Patients will be monitored as usual using the Venous International Normalised Ratio strategy. Practices will not be changed (i.e. prospective observation of real-life practices; according to recommendations, at least 1 Venous International Normalised Ratio per month will usually be performed) and patients will not receive any supplementary intervention specific to the trial. A reminder of good International Normalised Ratio practices will be provided to nurses and prescribers.
The present patent application relates detecting adverse medication interactions using a wearable device. In some embodiments, fall event data of a patient is obtained, the fall event data including a set of fall events experienced by the patient during a first time period. Medication data associated with the patient is also capable of being obtained. The medication data indicates a set of medications taken or prescribed to be taken by the patient during the first time period. Training data is configured to be generated for a prediction model based on the fall event data and the medication data, and the training data is capable of being provided to the prediction model. The prediction model is configured to estimate, based on the training data, a dependency between one or more medications and a risk of experiencing a fall event.
Systems and methods for determining a treatment action include recording batches of data in a replay buffer, each of the batches including a present state, a previous state and a previous action. A value of each action in a set of candidate actions is evaluated at the present state according to a probability that each action achieves a goal of resolving a patient condition or achieves an objective for treating the patient condition by using a value model head corresponding to the goal and the objective. The treatment action is determined from the set of candidate actions according to the value of each action. The treatment action is communicated to a user to treat the patient condition. An error of the value of each action is determined according to whether the previous state achieved by the previous action matches the goal of the objective. Parameters of the value model are updated according to the error.
BACKGROUND: Esthetic complications, such as capsular contracture and soft-tissue contour defects, hinder the desired outcomes of breast reconstruction. As subclinical infection is a prevailing theory behind capsular contracture, we investigated the effects of post-operative infections on these issues and revision procedures.
METHODS: We conducted a retrospective database study (2007-2021) on breast reconstruction patients from the MarketScan® Databases. Esthetic complications were defined by their associated revision procedures and queried via CPT codes. Severe capsular contracture (Grade 3-4) was defined as requiring capsulotomy or capsulectomy with implant removal or replacement. Moderate and severe soft-tissue defects were determined by the need for fat grafting or breast revision, respectively. Generalized linear models were used, adjusting for comorbidities and surgical factors (p < 0.05).
RESULTS: We analyzed the data on 62,510 eligible patients. Post-operative infections increased the odds of capsulotomy (OR 1.59, p < 0.001) and capsulectomy (OR 2.30, p < 0.001). They also raised the odds of breast revision for severe soft-tissue defects (OR 1.21, p < 0.001). There was no significant association between infections and fat grafting for moderate defects. Patients who had post-operative infections were also more likely to experience another infection after fat grafting (OR 3.39, p = 0.0018). In two-stage reconstruction, infection after tissue expander placement was associated with greater odds of infection after implant placement.
CONCLUSION: Post-operative infections increase the likelihood of developing severe soft-tissue defects and capsular contracture requiring surgical revision. Our data reinforce the role of infections in the pathophysiology of capsular contracture. Additionally, infections elevate the risk of subsequent infections after fat grafting for moderate defects, further increasing patient morbidity.
In this prospective pilot study, 70 patients will be recruited over a time period of one year, with non-traumatic thoracic pain in a pre-hospital setting. While the ambulance or MUG is transporting such a patient, he/she is asked (informed consent) if an extra blood sample can be taken for measuring troponin levels by the portable device of Roche (cobas h232®). This can be done during the same venipuncture needed for standard-of-care analysis of the two other blood samples used for troponin-T by the radiometer and the laboratory. An ECG is performed in the ambulance and when it is positive, a patient is diagnosed immediately with acute myocardial infarction (AMI) and will be to transported as fast as possible to the coronary care unit. The blood samples retrieved in the ambulance are transported to the lab and to the table top radiometer in the emergency unit. As stated before, an increasing number of patients with AMI are presenting without significant abnormalities on ECG. Therefore, the troponin-T levels in the blood sample will provide extra information to make an appropriate diagnosis. It is our hypothesis, that the Cobas h232 device will provide faster results and thus a faster diagnosis of AMI which benefit patients' outcome.
Neonatal hypoxia-ischemia encephalopathy (NHIE), an oxygen deprivation-mediated brain injury due to birth asphyxia or reduced cerebral blood perfusion, often leads to lifelong sequelae, including seizures, cerebral palsy, and mental retardation. NHIE poses a significant health challenge, as one of the leading causes of neonatal morbidity and mortality globally. Despite this, available therapies are limited. Numerous studies have recently demonstrated that ferroptosis, an iron-dependent non-apoptotic regulated form of cell death characterized by lipid peroxidation (LPO) and iron dyshomeostasis, plays a role in the genesis of NHIE. Moreover, recently discovered compounds have been shown to exert potential therapeutic effects on NHIE by inhibiting ferroptosis. This comprehensive review summarizes the fundamental mechanisms of ferroptosis contributing to NHIE. We focus on various emerging therapeutic compounds exhibiting characteristics of ferroptosis inhibition and delineate their pharmacological benefits for the treatment of NHIE. This review suggests that pharmacological inhibition of ferroptosis may be a potential therapeutic strategy for NHIE.